In a recent meeting of the U.S. Food and Drug Administration’s external advisory committee, all ten members voted to endorse the safety of Grail’s Galleri blood‑based cancer detection test. The panel, however, was divided on the test’s effectiveness, approving it by a 6‑4 margin.
Safety receives unanimous support
Each of the ten experts on the panel affirmed that Galleri meets the agency’s safety standards. The test, which requires a single blood draw, is intended for adults aged 50 and older and can screen for multiple cancer types simultaneously—an ability that no other FDA‑approved test currently offers in the United States.
Effectiveness vote reflects mixed views
When asked whether the evidence demonstrated sufficient efficacy, six members voted in favor and four voted against, resulting in a narrow endorsement. A separate vote on the overall risk‑benefit balance yielded a 7‑2 result, with one member abstaining, indicating that a majority believes the potential benefits outweigh the risks.
Study results underpin the discussion
Grail’s data come from two large clinical studies—one conducted in the United States and another in the United Kingdom. The U.S. trial reported that Galleri detected 35% of cancers within 12 months of testing and produced a very low false‑positive rate, with a specificity of 99.85%. The British study produced comparable findings, reinforcing the test’s promise for early cancer detection.
What the FDA’s next steps could look like
While the advisory panel’s recommendations are not binding, the FDA traditionally gives considerable weight to its experts’ opinions. A final decision on whether Galleri will be cleared for nationwide sale is expected in the coming months.
Implications for patients and providers
If approved, Galleri could become a valuable tool for early cancer screening, potentially catching disease at a stage when treatment is more effective. Physicians and patients alike will be watching the FDA’s final ruling closely, as the test’s ability to identify multiple cancers from a single blood sample could reshape screening practices across the country.
Industry and expert reactions
Grail representatives have highlighted the test’s high specificity and its capacity to reduce unnecessary follow‑up procedures. Independent experts, while supportive of the safety findings, urged caution, noting that the efficacy vote reflects ongoing questions about how the test’s detection rates translate into long‑term health outcomes.
The FDA’s deliberations on Galleri underscore the agency’s broader effort to evaluate innovative diagnostic technologies while ensuring they meet rigorous safety and efficacy standards for American patients.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
